ONDANSETRON

Usual Diluents

D5W, NS

Standard Dilution | [Amount of drug] | [Infusion volume] | [Infusion rate]

[All doses] | [50 ml] | [15 min]

- ZOFRAN Injection should be diluted in 50 mL of 5% Dextrose Injection or 0.9% Sodium Chloride Injection before administration.
- IVPB: Infuse diluted solution over 15-30 minutes; 24-hour continuous infusions have been reported, but are rarely used.

Chemotherapy-induced nausea and vomiting: Give first dose 30 minutes prior to beginning chemotherapy.

I.V. push: Prevention of postoperative nausea and vomiting: Single doses may be administered I.V. injection over 2-5 minutes as undiluted solution.

Note: Recent Update:
FDA Drug Safety Communication: New information regarding QT prolongation with ondansetron (Zofran):
http://www.fda.gov/Drugs/DrugSafety/ucm310190.htm

Stability / Miscellaneous

- store intact vial between 2°C and 30°C (36°F and 86°F). Protect from light.
- Ondansetron injection, USP is stable at room temperature under normal lighting conditions for 48 hours after dilution with the following I.V. fluids: 0.9% sodium chloride injection, 5% dextrose injection, 5% dextrose and 0.9% sodium chloride injection, 5% dextrose and 0.45% sodium chloride injection, and 3% sodium chloride injection. Although ondansetron injection, USP is chemically and physically stable when diluted as recommended, sterile precautions should be observed because diluents generally do not contain preservative. After dilution, do not use beyond 24 hours.
- Note: Parenteral drug products should be inspected visually for particulate matter and discoloration before administration whenever solution and container permit.

Precaution: Occasionally, ondansetron precipitates at the stopper/vial interface in vials stored upright. Potency and safety are not affected. If a precipitate is observed, resolubilize by shaking the vial vigorously.